Plus Therapeutics (PSTV) announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics announces publication of results on 186Re Obisbemeda
- Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda
- Plus Therapeutics sees $15M in gross proceeds from private placement
- Plus Therapeutics granted orphan designation for lung cancer treatment
- Plus Therapeutics advances Rhenium Obisbemeda